Suscribirse

Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity - 03/06/22

Doi : 10.1016/j.jaci.2022.04.002 
Leanne P.M. van Leeuwen, MD a, b, , Corine H. GeurtsvanKessel, MD, PhD a, , , Pauline M. Ellerbroek, MD, PhD c, , §, Godelieve J. de Bree, MD, PhD d, , §, Judith Potjewijd, MD e, , §, Abraham Rutgers, MD, PhD f, , §, Hetty Jolink, MD, PhD g, , §, Frank van de Veerdonk, MD, PhD h, , §, Eric C.M. van Gorp, MD, PhD a, b, Faye de Wilt, BSc a, Susanne Bogers, MSc a, Lennert Gommers, BSc a, Daryl Geers, MSc a, Anke H.W. Bruns, MD, PhD c, Helen L. Leavis, MD, PhD c, Jelle W. van Haga, BSc d, Bregtje A. Lemkes, MD, PhD d, Annelou van der Veen, BSc d, S.F.J. de Kruijf-Bazen, MSc e, Pieter van Paassen, MD, PhD e, Karina de Leeuw, MD, PhD f, Annick A.J.M. van de Ven, MD, PhD f, Petra H. Verbeek-Menken, BSc g, Annelies van Wengen, MSc g, Sandra M. Arend, MD, PhD g, Anja J. Ruten-Budde, PhD i, Marianne W. van der Ent, MSc j, P. Martin van Hagen, MD, PhD j, k, Rogier W. Sanders, PhD l, Marloes Grobben, MSc l, Karlijn van der Straten, MD l, Judith A. Burger, BSc l, Meliawati Poniman, MSc l, Stefan Nierkens, PhD m, n, Marit J. van Gils, PhD l, , Rory D. de Vries, PhD a, , , Virgil A.S.H. Dalm, MD, PhD j, k, , ,
a Department of Viroscience, Erasmus MC University Medical Center, Rotterdam, The Netherlands 
b Travel Clinic, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands 
c Department of Internal Medicine, UMC Utrecht, Utrecht, The Netherlands 
d Department of Infectious Diseases, Amsterdam UMC, Amsterdam, The Netherlands 
e Department of Internal Medicine, Division of Nephrology and Clinical Immunology, Maastricht UMC, Maastricht, The Netherlands 
f Department of Rheumatology and Clinical Immunology, UMC Groningen, Groningen, The Netherlands 
g Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands 
h Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands 
i Department of Biostatistics, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands 
j Department of Internal Medicine, Division of Allergy & Clinical Immunology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands 
k Department of Immunology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands 
l Department of Medical Microbiology and Infection Prevention, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands 
m Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands 
n Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands 

Corresponding author: Virgil A. S. H. Dalm, MD, PhD, Erasmus University Medical Center Rotterdam, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.Erasmus University Medical Center RotterdamDoctor Molewaterplein 40RotterdamThe Netherlands3015 GD

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Patients with inborn errors of immunity (IEI) are at increased risk of severe coronavirus disease-2019 (COVID-19). Effective vaccination against COVID-19 is therefore of great importance in this group, but little is known about the immunogenicity of COVID-19 vaccines in these patients.

Objectives

We sought to study humoral and cellular immune responses after mRNA-1273 COVID-19 vaccination in adult patients with IEI.

Methods

In a prospective, controlled, multicenter study, 505 patients with IEI (common variable immunodeficiency [CVID], isolated or undefined antibody deficiencies, X-linked agammaglobulinemia, combined B- and T-cell immunodeficiency, phagocyte defects) and 192 controls were included. All participants received 2 doses of the mRNA-1273 COVID-19 vaccine. Levels of severe acute respiratory syndrome coronavirus-2–specific binding antibodies, neutralizing antibodies, and T-cell responses were assessed at baseline, 28 days after first vaccination, and 28 days after second vaccination.

Results

Seroconversion rates in patients with clinically mild antibody deficiencies and phagocyte defects were similar to those in healthy controls, but seroconversion rates in patients with more severe IEI, such as CVID and combined B- and T-cell immunodeficiency, were lower. Binding antibody titers correlated well to the presence of neutralizing antibodies. T-cell responses were comparable to those in controls in all IEI cohorts, with the exception of patients with CVID. The presence of noninfectious complications and the use of immunosuppressive drugs in patients with CVID were negatively correlated with the antibody response.

Conclusions

COVID-19 vaccination with mRNA-1273 was immunogenic in mild antibody deficiencies and phagocyte defects and in most patients with combined B- and T-cell immunodeficiency and CVID. Lowest response was detected in patients with X-linked agammaglobulinemia and in patients with CVID with noninfectious complications. The assessment of longevity of immune responses in these vulnerable patient groups will guide decision making for additional vaccinations.

El texto completo de este artículo está disponible en PDF.

Key words : Inborn errors of immunity, primary immunodeficiency disorders, SARS-CoV-2, mRNA-1273 COVID-19 vaccine, immunogenicity, antibody response, T-cell response, CVID, CID, XLA

Abbreviations used : CID, COVID-19, CVID, GMT, IEI, RBD, SARS-CoV-2, SPAD, S, XLA


Esquema


 This study was funded by ZonMw (grant no. 10430072010006), EudraCT number 2021-000515-24.
 Disclosure of potential conflict of interest: M. J. van Gils received funding from the Amsterdam UMC Fellowship to support her research activities. J. Potjewijd received a grant from GlaxoSmithKline (GSK) for an improvement of clinical care project, received support from Prothva Biosolutions for attending meetings and cover of travel expenses, and participates in an Advisory Board for Janssen. A. A. J. M. van de Ven received a grant of the Stichting voor Afweerstoornissen (SAS, Dutch Patients Organization for inborn errors of immunity) and lecture honoraria from Takeda Pharmaceutical Company. S. F. J. de Kruijf-Bazen reported honoraria for lectures and support for attending meetings and/or travel from Takeda Pharmaceutical Company and participated in an advisory board for Takeda Pharmaceutical Company. F. van de Veerdonk received a grant from ZonMW for a study on lanadelumab in COVID-19, and consulting fees from GSK made to his department. H. L. Leavis received a Takeda Pharmaceutical Company research grant and consulting fees from Takeda Pharmaceutical Company made to her institution. P. M. van Hagen is cochair of the medical board of the International Patients Organisation for Primary Immunodeficiencies. V. A. S. H. Dalm received consulting fees from GSK for Advisory board meetings and honoraria for lectures from Takeda Pharmaceutical Company. The rest of the authors declare that they have no relevant conflicts of interest.


© 2022  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 149 - N° 6

P. 1949-1957 - juin 2022 Regresar al número
Artículo precedente Artículo precedente
  • Preschool wheeze phenotypes from birth cohorts: Where do we go from here?
  • Jason S. Debley
| Artículo siguiente Artículo siguiente
  • The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin
  • Aaron L. Miller, Nicholas L. Rider, Richard B. Pyles, Barbara Judy, Xuping Xie, Pei-Yong Shi, Thomas G. Ksiazek

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.